{
    "relation": [
        [
            "",
            "Number of Participants [units: participants]",
            "Age, Customized [units: Participants]",
            "18 years to 44 years",
            "45 years to 64 years",
            "Greater than or equal to 65 years",
            "Gender [units: Participants]",
            "Female",
            "Male"
        ],
        [
            "Axitinib + Gemcitabine (Phase 1 Lead-In)",
            "8",
            "",
            "0",
            "5",
            "3",
            "",
            "1",
            "7"
        ],
        [
            "Axitinib + Gemcitabine",
            "69",
            "",
            "2",
            "31",
            "36",
            "",
            "34",
            "35"
        ],
        [
            "Gemcitabine",
            "34",
            "",
            "4",
            "20",
            "10",
            "",
            "18",
            "16"
        ],
        [
            "Total",
            "111",
            "",
            "6",
            "56",
            "49",
            "",
            "53",
            "58"
        ]
    ],
    "pageTitle": "AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00219557?sect=Xj015&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 8,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042991076.30/warc/CC-MAIN-20150728002311-00151-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 868170366,
    "recordOffset": 868153972,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Phase 1 Participant Flow for 2 periods Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks. Gemcitabine Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks. Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks. Axitinib + Gemcitabine Axitinib (AG-013736) 5 milligram (mg) tablet orally twice daily (BID) starting from Day 3 of Cycle 1, in cycles of 4 weeks. Gemcitabine 1000 milligram/square meter (mg/m^2) 30 minutes intravenous (IV) infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks. Axitinib + Gemcitabine (Phase 1 Lead-In) Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered.",
    "textAfterTable": "\u00a0 34 \u00a0 Treated \u00a0 \u00a0 0 \u00a0 \u00a0 68 \u00a0 \u00a0 31 \u00a0 COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 1 \u00a0 NOT COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 69 \u00a0 \u00a0 33 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 21 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 15 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 22 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Death \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}